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AMR gene reference database consisting of up-to-date protein and gene nomenclature, a set of 23 hidden Markov models (HMMs), and a curated protein family hierarchy. Currently, the 24 Bacterial Antimicrobial Resistance Reference Gene Database contains 4,579 antimicrobial 25 resistance gene proteins and more than 560 HMMs. 26
Here, we describe AMRFinder, a tool that uses this reference dataset to identify AMR genes. 27
To assess the predictive ability of AMRFinder, we measured the consistency between predicted 28 AMR genotypes from AMRFinder against resistance phenotypes of 6,242 isolates from the 29 National Antimicrobial Resistance Monitoring System (NARMS). This included 5,425 30 Salmonella enterica, 770 Campylobacter spp., and 47 Escherichia coli phenotypically tested 31 against various antimicrobial agents. Of 87,679 susceptibility tests performed, 98.4% were 32 consistent with predictions. 33
To assess the accuracy of AMRFinder, we compared its gene symbol output with that of a 34 Introduction 55
Antimicrobial resistance (AMR) is a major public health problem, with an estimated 23,000 56 deaths annually in the U.S. attributable to antimicrobial resistant infections 57 (https://www.cdc.gov/drugresistance/threat-report-2013/index.html). The continued evolution of 58 multi-drug resistance ensures that AMR will continue to be a health challenge for years to come. 59
As described in the National Strategy on Combating Antibiotic Resistant Bacteria report 60 (https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-61 resistant_bacteria.pdf), there is a critical need to understand how AMR is related to bacterial 62 genotype, both to enhance AMR mechanism discovery and to enable AMR diagnostics. One key 63 method to establish this link is genome sequencing, which can also be used for surveillance 64 purposes. 65
Traditionally, AMR has been identified using phenotypic assays. The gold standard for 66 measuring antimicrobial susceptibility is based on standardized dilution-or diffusion-based in 67 vitro antimicrobial susceptibility testing (AST) methods, where extensive research and testing 68 have been performed to correlate AST measurements with clinical outcomes (1) Increasingly, 69 molecular methods are being used in resistance surveillance and in some cases also to guide 70 clinical therapy. These range from PCR detection of known resistance elements (2) to mass 71 spectrometry-based methods (3-7). Whole genome shotgun sequencing (WGS) has been 72 integrated into the clinical and public health settings, though the use of WGS has focused 73 primarily on outbreak identification and tracking (8, 9) . Along with epidemiological uses, there 74 is great potential for the use of WGS to aid and guide AMR detection (10) (11) (12) (13) (14) (15) . Accurate 75 assessment of AMR gene content enables the discovery of novel resistance variants and can 76 serve as the basis for predicting resistance phenotypes without the need for time consuming 77 phenotypic tests (11, 16, 17) . 78 metallo-beta-hydrolases as metallo-beta-lactamases (21)). HMM approaches facilitate a 86 hierarchical classification of AMR proteins, from alleles to gene families, but curation and 87 validation of HMM libraries are required. Tools also differ based on whether they analyze 88 nucleotide or protein sequence. Additionally, some tools are only available through a web-89 interface, while others can be operated on local servers providing more flexibility to users. 90
Researchers attempting to use currently available AMR databases must choose between these 91 different database resources. Some contain collections of alignments of resistance genes for use 92 in HMMs (20) . Others consist of collections of nucleotide or protein sequences of either 93 individual resistance genes or resistance-related mobile elements (22, 23) . Some databases are 94 actively curated such as the CARD (23, 24) , ResFinder (22) , and the Lahey Clinic database 95 (https://www.lahey.org/Studies/ ; the latter is now hosted and maintained by NCBI, as part of the 96 NCBI's Bacterial Antimicrobial Resistance Reference Gene Database), while others are not 97 actively updated. Separate groups curate different classes of genes, and even a single class of 98 genes can be curated by multiple groups (e.g., beta-lactamases). In addition, some data resources 99 include allelic variation of housekeeping genes that can confer or contribute to resistance, while 100 others focus exclusively on acquired resistance mechanisms. Assessing and comparing these 101 resources and tools is also challenging as there are few high-quality strain collections that have 102 been extensively genotyped and phenotyped, and that are also publicly available. 103
Here, we describe the development of a comprehensive AMR gene database, the Bacterial 104 Antimicrobial Resistance Reference Gene Database, and the development of AMRFinder, an 105 AMR gene identification tool, along with publicly available datasets to test AMR gene detection 106 methods. To identify AMR genes from sequence data, we created over 560 AMR HMMs (21) 107 and curated over 4,579 AMR protein sequences, placing both in a hierarchical framework of 108 gene families, symbols, and names in collaboration with multiple groups including CARD (21). 109
We then developed AMRFinder to leverage both the content and structure of this database to 110 accurately identify and name AMR gene sequences. To validate this system, we used a collection 111 of isolates from the NARMS program that have undergone extensive susceptibility testing and 112 whole genome shotgun assembly, and we also compared AMRFinder performance with a 113 version of ResFinder 2.0 released in 2017. 114
Methods 115

AMR gene database 116
The Bacterial Antimicrobial Resistance Reference Gene Database contains a hierarchy of AMR 117 protein families and is stored in NCBI's RefSeq database (21). Each protein, and each protein 118 family, has a curated name and gene symbol where appropriate. Gene symbols can point to more 119 than one protein sequence, while alleles point to one unique amino acid sequence. For many 120 families, we have constructed protein HMMs that identify these protein families. When 121 necessary, the protein sequence has been manually verified to be full-length and to have the 122 appropriate start site. The proteins are arranged in protein family hierarchies based on protein 123 homology and function. 124
Our collection of AMR proteins is derived from multiple sources, including the compilation 125 of beta-lactamase alleles and Qnr family quinolone resistance protein alleles compiled by the 126 include the 27 previously covered by Lahey, the ADC and PDC families, as well as the newly 133 assigned families CMH, CRH, and FRI. Since January 2016, NCBI has assigned 676 new beta-134 lactamase alleles. These newly assigned alleles as well as those previously curated are 135 incorporated into our AMR gene database. We obtained compilations of resistance genes for 136 several classes of ribosome-targeting antibiotics from Dr. Marilyn Roberts [(26) The 4,528 resistance proteins in our database as of this writing confer resistance to 34 classes 144 of antimicrobials and disinfectants, and are encoded by over 800 gene families. All underlying 145 nucleotide records contain complete coding sequence and are not derived from synthetic 146 constructs. Nucleotide sequences were oriented with the AMR protein coding region on the 147 positive strand, and records were constructed, where possible, to include an additional 100bp on 148 either side of the coding region to assist in the design of primers. Protein records were created as 149 described previously (21). This collection has a standardized nomenclature to provide maximal 150 functional information as well as ease of bioinformatic use, and is found under in our Reference 151 Gene Browser (https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/) as well as RefSeq 152 BioProject PRJNA313047 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047). 153
AMR HMM construction 154
Groups of related AMR proteins with similar sequences and similar gene symbols as taken 155 from our various sources were aligned using MUSCLE (29) or Clustal W (30), then viewed, 156 trimmed, and culled of mis-assigned, redundant, frameshifted, or fragmentary sequences, using 157
Belvu (31). The resulting curated multiple sequence "seed" alignments were used to construct 158 protein profile HMMs, using the HMMER3 package (http://hmmer.org/). In some cases, BLAST 159 or HMM searches recruited additional sequences that were judged valid to add to the seed 160 alignments so that the scores obtained in HMM search results could more clearly separate true 161 family members from outgroup sequences. The ResFams (20) library of HMMs, based on 162 sequences taken from CARD sequences and clustered by their CARD antibiotic resistance 163 ontology assignments, provided important early assistance in recognizing putative AMR proteins 164 and grouping them into homology families. However, to create a hierarchical classification 165 system for AMR proteins, with sufficiently fine divisions of recognized families and cutoffs 166 values that could prove trustworthy while searching very large data sets, we created, calibrated, 167 and annotated an entirely new HMM library, available at 168 https://ftp.ncbi.nlm.nih.gov/hmm/NCBIfam-AMRFinder/. The literature was reviewed, 169 molecular phylogenetic trees and search results were examined, and an informative protein name 170 was selected for each HMM built to represent a family of AMR proteins. These HMMs support 171 correct functional annotation of AMR proteins for RefSeq prokaryotic genomes (21). 172
Identifying acquired AMR genes 173
Protein searches: AMRFinder-prot uses the database of AMR gene sequences, HMMs, the 174 hierarchical tree of AMR protein designations, and a custom rule-set to generate names and 175 coordinates for AMR genes, along with descriptions of the evidence used to identify the 176 sequence. Software and documentation are available at https://github.com/ncbi/amr and 177 https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/. Genes are 178 reported with the following procedure after both HMMER and BLASTP searches are run. 179 BLASTP matches: In AMRFinder, BLASTP (32, 33) is run with the -task blastp-fast -180 word_size 6 -threshold 21 -evalue 1e-20 -comp_based_stats 0 options against the AMR gene 181 database described above. Exact BLAST matches over the full length of the reference protein 182 are reported. If there is no exact match, then the following rules are applied: Matches with < 90% 183 identity or with < 50% coverage of the protein are dropped. If the hit is to a fusion protein then at 184 least 90% of the protein must be covered. A BLAST match to a reference protein is removed if it 185 is covered by another BLAST match which has more identical residues or the same number of 186 identical residues, but to a longer reference protein. A single match is chosen as the best of what 187 remains sorting by the following criteria in order (1) if it is exact; (2) has more identical residues; 188
(3) hits a shorter protein; or (4) the gene symbol comes first in alphabetical order. 189 HMM matches: HMMER version 3.1b2 (http://hmmer.org/) is run using the --cut_tc -Z 190 10000 options with the HMM database described above. HMM matches with full_score < TC1 191 or domain_score < TC2 are dropped. All HMM matches to HMMs for parent nodes of other 192 HMM matches in the hierarchy are removed. The match(es) with the highest full score are kept. 193
If there is an exact BLAST match or the family of the BLAST match reference protein is 194 descendant of the family of the HMM then the information for the nearest HMM node to the 195 BLAST match are returned. 196
Translated DNA searches: Translated alignments using BLASTX of the assembly against the 197 AMR protein database were used to help identify partial, split, or unannotated AMR proteins 198 using the -task tblastn-fast -word_size 3 -evalue 1e-20 -seg no -comp_based_stats 0 options. The 199 algorithm for selecting hits is as described above for proteins, but note that HMM searches are 200 not performed against the unannotated assembly. 201
Nucleotide searches: Nucleotide-nucleotide BLAST searches were also performed for evaluation 202 purposes, although this is not built into AMRFinder. We collected the nucleotide sequences for 203 all proteins in GenBank with sequences identical to those in the AMR database. The genome 204 assembly for each isolate was masked at locations identified as AMR genes by AMRFinder 205 before aligning the remainder against the nucleotide sequences we collected above. Hits were 206 combined to determine coverage of the reference protein and all 7 hits with > 50% length and > 207 90% sequence similarity to a reference sequence were selected for analysis. 208 Table S1 and are deposited in the Sequence Read Archive, or were independently 215 assembled and submitted to GenBank prior to the start of the analysis. 216
Samples
There were a small number of isolates whose excessive differences between MIC tests and 217 predictions of resistance suggested artifacts from resistance gene loss, sample swaps, testing 218 errors, mixed cultures, or other confounding factors. We eliminated isolates where resistance 219 calls differed from the gene-based prediction for all tested members of three or more drug classes 220 defined as aminoglycosides, beta-lactams, lincosamides, ketolides, macrolides, phenicols, 221 quinolones, sulfonamides, tetracyclines, and trimethoprim-sulfamethoxazole. This filter removed 222 38 isolates from the analyses (0.6%, Figure 1 ). 223
Genome assembly and annotation 224
Illumina whole-genome shotgun reads were assembled using SPAdes v.3.5.0 using the 225 default parameters (35). To be included in the study we required the isolate assemblies to meet 226 the following criteria: (1) one and only one species-appropriate, full-length, gyrA gene; (2) were aligned back to the assembly with BWA version 0.7.10-r789 using the MEM algorithm and 231 default parameters (37). SAMtools version 1.3.1 was then used to convert alignments to read-232 depths for each base (38). Genomes were annotated using NCBI's PGAP 2.0 pipeline (21, 39). 233
For 540 isolates, we used genome assemblies already deposited in GenBank (Table S1) . 234
Combining results 235
First, redundant equal-scoring hits to the same protein or identical location on the assembly 236 were removed. Next, translated BLAST hits that overlapped over more than 75% of their length 237
with AMRFinder-prot hits were removed as duplicates. Finally, nucleotide BLAST hits that 238 overlapped over more than 75% of their length with either AMRFinder-prot or translated 239 BLAST hits were removed as duplicates. 14,984 (98.19%) AMR genes were identified by the 240 annotation-based protein AMRFinder, while 268 (1.77%) were identified by translated DNA 241 BLAST. The remaining 7 hits (0.046%) were partial proteins identified only by nucleotide 242
BLAST. 243
Contig filtering 244
Reads for each isolate were aligned back to the assembly using BWA version 0.7.10-r789 245 using the MEM algorithm and default parameters (40). SAMtools version 1.3.1 was then used to 246 convert alignments to read-depths for each base (38). Using this data genome-wide and per-247 contig average read-depths were calculated for filtering. AMR genes identified above were 248 filtered and removed from analysis if its read-depth of the contig containing a given AMR gene 249 was < 1/10th of the average per-base read-depth for the entire assembly. 250
Identifying point mutations 251
Point mutations in three structural genes that confer resistance in C. coli and C. jejuni were. 252 examined: gyrA, 50S ribosomal protein L22, and 23S rRNA (11). We identified putative 253 resistance mutations by blasting the protein or nucleotide sequences against the listed accessions 254 and predicted resistance based on the presence of the listed known resistance alleles at any of the 255 listed offsets. The gene gyrA was screened (AJW58405.1 and YP_002344422.1) for the 256 mutations T86I, T86K, T86V, D90N, D90Y, P104S, and C257T, which predict resistance to 257 quinolones. For the 50S ribosomal protein L22 (AJW59082.1 and YP_002345068.1) we 258 predicted resistance to macrolides due to changes at positions A84D, G86E, G86V, A88E, and 259 A103V. The 23S rRNA (CP01115.1) was screened for those C. jejuni 23S mutations, A2074C, 260 A2074G, A2074T, A2075G, and C2627A, which were expected to confer resistance to 261 macrolides(41-43). To assess if ciprofloxacin resistance in S. enterica could be attributed to 262 point mutations, we screened gyrA (WP_001281271.1; A67P, D72G, V73I, G81C/S/H/D, 263 D82G/N, S83Y/F/A, D87N/G/Y/K, S97P, L98V, A119S/E/V, A131G, E139A), gyrB 264 (WP_000072047.1; Y421C, R438L, S464Y/F, E466D), parC (WP_001281910.1; T66I, G78D, 265 S80R/I, E84K/G), and parE (WP_000195318.1; M438I, E454G, S458P, V461G, H462Y, 266 A499T, V514G, V521F) for mutations expected to confer resistance (44) (45) (46) (47) . 267
Correlation of antimicrobial susceptibility phenotypes with resistance gene content 268
After all resistance genes were identified, isolates exhibiting phenotypic resistance were 269 correlated with the predicted phenotype based on presence or absence of resistance genes or 270 point mutations for each antibiotic (see Table S4 for predictions). Predicted phenotypes were 271 scored as either resistant (R) or susceptible (S), with the presence of one or more resistance-272 conferring genes yielding a prediction of "R". These were compared to the gold standard 273 observed phenotypic results, with observed susceptibility results of intermediate (I) treated as 274 "S", with the exception of ciprofloxacin in S. enterica, for which I values were treated as 275 resistant, since previous work has indicated that one or more resistance genes or point mutations 276 are associated with an intermediate susceptibility phenotype (48, 49) . 277
AMRFinder-ResFinder comparisons 278
AMRFinder blasts resistance gene protein sequences, either against a set of annotated 279 proteins or a nucleotide sequence, while Resfinder uses a nucleotide database, and blasts that 280 database against a nucleotide sequence (e.g., a bacterial genome). In addition, Resfinder reports 281 the 'highest-scoring' hit, even if the underlying sequence does not support such a precise claim 282 (e.g., calling a novel OXA allele "OXA-61"), while the hierarchical gene structure of 283
AMRFinder will attempt to identify the appropriate gene name that does not provide an incorrect 284 or overly precise name. To compare the output of AMRFinder to ResFinder, we first determined 285 if these two methods called AMR genes at nearly identical coordinates on the same genome (the 286 absolute difference in lengths could be no more than 40 bp). We used Resfinder 2.0, with the 287 database downloaded on Nov. 15, 2017 and compared it with AMRFinder with the database 288 locked on Feb. 2, 2017. For Resfinder, the default settings of 90% nucleotide similarity and a 289 60% minimum length were used. The particular version of the AMRFinder gene database used in 290 this study can be found at 291 ftp://ftp.ncbi.nlm.nih.gov/pathogen/Technical/AMRFinder_technical/feldgard_et_al_2018_amrd 292 b.tar.gz. AMRFinder parameters used include a 90% nucleotide similarity and 50% minimum 293 length for matching, and 40 disinfectant and other resistance genes were included in AMRFinder 294 that were not in ResFinder 2.0. This allowed us to identify instances when the same gene 295 occurred multiple times in a genome in instances where one copy was missed or misidentified by 296 either method. We then compared gene symbols produced by each method. Where gene 297 symbols did not agree, we assigned them to one of four categories: (1) Synonyms were cases 298 where the identical protein was called by both methods, but the name differed (e.g., many 299 aminoglycoside modifying enzymes, such as strA and aph(3'')-Ib).
(2) Underspecified calls 300 occurred when the protein was 100% identical to a known, named protein, but one method did 301 not describe it with sufficient resolution (e.g., blaTEM-1 is miscalled as blaTEM). (3) Overspecified 302 calls were cases where the correct name was a less specific gene symbol, when the method 303 provided an overspecified symbol (e.g., a novel blaTEM family allele is miscalled as blaTEM-1). (4) 304
Incorrect calls occurred when an incorrect gene symbol was ascribed to a protein (e.g., blaOXA-193 305 is miscalled as blaOXA-61). 306
Antimicrobial susceptibility testing 307
Minimum inhibitory concentrations were measured using the Sensitire™ system and 308 susceptibility panels designed specifically for NARMS surveillance (50). E. coli and S. enterica 309 were tested for susceptibility to amoxicillin-clavulanic acid, ampicillin, azithromycin, cefoxitin, 310 ceftriaxone, chloramphenicol, ciprofloxacin, trimethoprim-sulfamethoxazole, gentamicin, 311 nalidixic acid, streptomycin, sulfisoxazole, and tetracycline; some Salmonella isolates were 312 screened against amikacin, ceftiofur, kanamycin, and meropenem depending on the composition 313 of the NARMS panel at the time of testing. Campylobacter spp. were screened for susceptibility 314 to azithromycin, ciprofloxacin, clindamycin, erythromycin, florfenicol, gentamicin, nalidixic 315 acid, telithromycin, and tetracycline. 316
The breakpoints used for susceptibility testing were CLSI standard breakpoints. For 317 antibiotics that lack CLSI breakpoints, breakpoints established by the NARMS Working Group 318 were used (Table S2, S3) . 319
Results 320
We compiled, curated, and publicly released a hierarchical database of AMR gene families, 321 names, sequences, and HMMs with a consistent naming scheme and hierarchical structure called 322 the Bacterial Antimicrobial Resistance Reference Gene Database 323 (https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/). We also developed AMRFinder to 324 use the AMR protein sequences, HMMs, the hierarchy of gene families and a custom rule-set to 325 generate a report of the names, symbols, and coordinates of acquired AMR genes along with 326 descriptions of the evidence used to identify the sequence 327 (https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/ ). 328
To verify and validate the results of the AMRFinder system, we analyzed a collection of 329 isolates, sequenced, and susceptibility tested as part of the NARMS program. We then compared 330 the resistance patterns predicted by AMR genes identified in the genome sequence to the results 331 of the phenotypic susceptibility tests. We further compared the resistance gene calls made by 332 AMRFinder to calls from the commonly used resistance gene finding tool ResFinder (22). 333
A total of 6,301 NARMS isolates with both phenotypes and whole-genome shotgun 334 sequences were compiled, 59 were removed for quality reasons described above, leaving 6,242 335 isolates for this analysis (Figure 1) . After assembly and annotation, AMRFinder was used to 336 generate a list of 16,003 AMR gene calls, yielding 132 unique genes and alleles. Resistance 337 predictions for the 132 genes and alleles observed in the set of 6,242 isolates were compiled 338 from the literature (Table S4 ) and used to predict resistance. 339
Overall consistency 340
For the entire set, there were 87,679 susceptibility tests performed, 98.4% (86,276) were 341 consistent with predictions based on the resistance genotypes (acquired resistance genes, and, 342 when tested, point mutations. Of the 13,903 tests that were predicted to be resistant, 95.5% were 343 observed to be resistant (PPV = 0.955), while of the 73,776 tests expected to be susceptible, 344 99.2% were observed to be susceptible (NPV = 0.992; Table 1 ). 2,136 of the 6,242 isolates 345 (34.2%) were pan-susceptible. E. coli isolates had the highest consistency with 99.7% (656/658) 346 of susceptibility tests predicted by the resistance genotype. Within S. enterica, 98.0% of 347 susceptibility tests were consistent with the resistance genotype, with PPV = 0.94 and NPV = 348 0.992 (Table 2) . No resistance among E. coli and S. enterica isolates to amikacin or meropenem 349 was observed or predicted. C. coli had the lowest consistency, with 96.7% of susceptibility tests 350 consistent with the resistance genotype, with a PPV of 0.904 and an NPV of 0.982 (Table 3) . 351 98.9% of phenotypes were accurately predicted for C. jejuni, with PPV = 0.971 and NPV = 352 0.992 (Table 4 ). Gentamicin and streptomycin susceptibility calls in S. enterica were the most 353 common incorrect predictions, accounting for 38% of inconsistent calls (532/1,403). 17% of all 354 isolates (1,053) had one or more inconsistent calls between genotype and phenotype. 355
Quinolone resistance 356
None of the 47 E. coli isolates were resistant to either nalidixic acid or ciprofloxacin, nor 357
were they predicted to be. S. enterica displayed high consistency for both ciprofloxacin and 358 nalidixic acid (Table 2) . When decreased susceptibility (R or I) is used as the breakpoint for 359 ciprofloxacin (51), S. enterica isolates had high positive predictive values (PPV = 0.891) and 360 high negative predictive values (NPV = 0.997). For nalidixic acid, the positive predictive value 361 was quite low (PPV = 0.3). Thirty-five qnr + isolates (71.4%) were susceptible to nalidixic acid, 362 but they had an MIC of one doubling dilution below the nalidixic acid breakpoint of 32 µg/ml; 363 thirteen qnr + isolates were resistant to nalidixic acid; previous work indicates that qnr loci might 364 not be very effective at conferring resistance to nalidixic acid (52). Point mutations in gyrA and 365 other genes associated with ciprofloxacin were not used for the determination of nalidixic acid 366 susceptibility, as it was unclear from some previous studies if these mutations also confer 367 resistance to nalixidic acid (48, 49) . However, of the 80 isolates that had ciprofloxacin resistance 368 mutations, 79 were resistant to nalidixic acid. 369
In C. coli and C. jejuni, fluoroquinolone resistance was associated with point mutations, 370 not acquired genes (Tables 3, 4 ). Based on previous reports (11), we examined the relationship 371 between gyrA mutations previously determined to confer fluoroquinolone resistance and 372 fluoroquinolone resistant isolates among these Campylobacter spp. isolates. All but two 373 fluoroquinolone resistant and no fluoroquinolone susceptible C. coli isolates possessed a GyrA 374 T86I mutation (Table S5 ). In C. jejuni, 84/85 isolates with GyrA T86I mutations were resistant 375 to ciprofloxacin, and 83/85 were resistant to nalidixic acid; three C. jejuni isolates without 376 known fluoroquinolone resistance mutations were resistant to both fluoroquinolones; no unique 377 mutations were correlated with these three isolates. 378
Thus in S. enterica, presence of qnr genes or QRDR mutations conferred either resistance 379 or decreased susceptibility to ciprofloxacin, while in Campylobacter spp. gyrA mutations 380 conferred resistance. 381
Macrolides and lincosamides 382
Only six of eleven S. enterica isolates predicted to be azithromycin resistant were resistant. 383
These six resistant isolates carried mph(A); however, one azithromycin susceptible isolate also 384 carried mph(A). The other four susceptible isolates carried either the ere(A) or abc-f resistance 385 genes; these isolates did not have elevated MICs near the top end of the susceptible range. 386
All C. jejuni were susceptible to azithromycin, erythromycin, and telithromycin, with only 387 six C. jejuni displaying resistance to clindamycin (Table 4 ). None of the clindamycin resistant 388 C. jejuni isolates had any known resistance mutations or unique mutations suggesting novel 389 resistance mutations in either 23S or the 50S/L22 subunit (Table S5 ). Macrolide resistance was 390 far more common in C. coli (Table 3) , with most resistant isolates possessing a A2075G 391 mutation in 23S (Table S6) , as has been observed previously (11). 392
Decreased amoxicillin-clavulanic acid susceptibility in S. enterica 393
As expected, we observed that 718 out of 725 S. enterica isolates (99.0%) with one or more 394 blaCMY-family genes were resistant to amoxicillin-clavulanic acid. As observed previously (51), 395 other beta-lactamases conferred decreased or intermediate susceptibility to amoxicillin-396 clavulanic acid (Fig. 3) 
Aminoglycoside susceptibility in Salmonella 403
Overall, the presence or absence of acquired gentamicin and kanamycin resistance genes was 404 a good predictor of susceptibility phenotypes (Table 2) . Of the 2,820 Salmonella that were 405 tested for susceptibility to amikacin, none were resistant, nor were they predicted to be resistant. 406
However, we noticed that several reported gentamicin and kanamycin resistance genes conferred 407 decreased susceptibility to gentamicin and kanamycin even if the MICs were not high enough to 408 qualify as resistant (Fig 4a, b) . The majority of aac(3)-IV + isolates (36/47) and 26% of ant(2'')-409 Ia + isolates displayed intermediate susceptibility to gentamicin. Many aac(6')-Ib + isolates were 410 susceptible to gentamicin, but the MICs of these isolates were higher than isolates lacking known 411 resistance genes. While aac(6')-Ib family enzymes, other than aac(6')-Ib4, do not confer 412 resistance to gentamicin, they are known to confer resistance to some of the individual 413 components of gentamicin, such as gentamicin C1a and C2, and thus these genes might decrease 414 susceptibility to gentamicin (53). While most kanamycin resistance genes were associated with 415 phenotypic resistance, 13% of ant(2'')-Ia + isolates had intermediate susceptibility. 416
As noted previously, streptomycin susceptibility calls accounted for a large fraction of the 417 inconsistent calls, with many such isolates containing putative streptomycin genes. There were 418 no obvious direct relationships between particular resistance genes and streptomycin 419 susceptibility (see Table S7 ). We examined whether partial genes (defined as 50%-90% of the 420 closest reference protein length) affected susceptibility calls. Partial genes only accounted for 421 6.4% of streptomycin discrepancies, suggesting this observation is not due to potential non-422 functional genes. While the mechanism of discordance between streptomycin resistance genes 423 and susceptibility is unclear, this relationship has been observed in multiple surveys of 424
Enterobacteriaceae (14, 16, 51, 54, 55) . [also see S. 8] 425
AMRFinder-ResFinder comparison 426
ResFinder is a widely used AMR determinant detection program(22). To assess the relative 427 accuracy of AMRFinder we compared the gene symbol calls at similar positions in the two tools. 428
As described in Methods, discrepant gene symbol calls were classified into four different 429 categories: synonyms, overspecification (e.g., calling a novel or partial blaTEM allele as blaTEM-1), 430 underspecification (e.g., calling an actual blaTEM-1 allele a blaTEM -family allele), and miscalls 431 (e.g., mislabeling a full-length, 100% identical sequence as a different, known full-length 432 sequence). 433
Overall, out of 14,023 AMR genes identified by both AMRFinder and ResFinder there were 434 1,229 gene symbol discrepancies (Tables 5, S8 ). These discrepancies could be mapped to 42 435 gene symbols, out of a total of 132 unique AMRFinder gene symbol calls. ResFinder 436 misidentified 247 genes with an exact match to a known AMR gene or allele (e.g., 437
misidentifying blaOXA-193 as blaOXA-61), and over-specified the gene symbol in 977 cases, 438 representing 18 misidentified gene symbols and 21 overspecified gene symbols out of the set of 439 132 unique AMR gene symbols. In five cases, AMRFinder underspecified the gene symbol, 440
representing three underspecifications out of the set of 132 unique AMR protein symbols. 441
The ResFinder misclassifications resulted from either the absence of the matching sequence 442 in the ResFinder database used in this study or a lack of correspondence between the closest 443 nucleotide hit and actual observed sequence. For example, 32 aac(6')-Ib family genes, including 444 22 known, 100% identity aac(6')-Ib4 sequences, were miscalled as aac(6')-Ib-cr. The gene 445 aac(6')-Ib-cr contributes to decreased fluoroquinolone susceptibility and confers amikacin and 446 tobramycin resistance, while aac(6')-Ib4 does not confer resistance or decreased susceptibility to 447 amikacin, ciprofloxacin, or tobramycin. We would note that none of the sixteen S. enterica 448 aac(6')-Ib4 + isolates that also were tested for susceptibility to amikacin were resistant to 449 amikacin, supporting the AMRFinder call of aac(6')-Ib4. In 977 instances, ResFinder 450 overspecified the gene symbol as it calls the closest hit as the correct gene symbol. Many of 451 these were novel, unnamed allelic variants of beta-lactamase families (n = 699; Table S8 ), and 452
Resfinder reported the closest hit (e.g., blaOXA-61 when a novel blaOXA sequence was 453 observed). 454
We also examined the loci that were missed by either ResFinder or AMRFinder. ResFinder 455 did not find 1,147 AMR loci that AMRFinder identified ( Table 6 ). Most of the missed loci 456 (81.2%) belonged to drug or disinfectant classes that ResFinder does not cover, bleomycin and 457 quarternary ammonium compounds. Bleomycin resistance is included in the AMRFinder 458 database and is highly associated with the clinically relevant NDM family carbapenemases (56), 459 although both databases do look directly for NDM genes, while qac enzymes can be linked to 460 multiple resistance genes (57). The next largest class belonged to AMR genes that were not 461 represented in the ResFinder database (8.8%). The default setting length of 60% of the reference 462 sequence also resulted in 111 missed calls. Of 66 genes not found by ResFinder that could be 463 assessed by susceptibility data (out of the total of 111), 53 genes were consistent with the 464 susceptibility data (associated with a resistant phenotype), while thirteen were not. 465
AMRFinder missed 16 loci that ResFinder found. In all 16 cases, these were frameshifts or 466 in-frame stop codons that resulted in a translated protein that either was not identified at all or 467 had a stop codon position that differed from the ResFinder stop position by more than 40 bp. Of 468 the three loci that AMRFinder missed that were assessed phenotypically, all of which were 469 frameshifts, two were resistant in spite of the apparent frameshift, while one was susceptible. 470
There were also 21 instances of an aph(6)-I like gene that was divergent from AMR genes in 471 either the ResFinder or the AMRFinder protein database. Due to this divergence, the two 472 systems identified proteins that differed in length and thus had divergent start and stop sites, and 473 were therefore called as misses. 474
Discussion 475
We developed and populated a highly curated database with hierarchical structure for AMR 476 proteins, with tuned cutoffs and associated hierarchical names. AMRFinder uses this AMR 477 protein database, HMMs, a hierarchy of AMR protein families, and a custom rule-set to identify 478 AMR genes. In addition, AMRFinder reports the evidence used to make the determination users 479 can evaluate its strength and their confidence in the calls. 480
We observed high consistency between the presence of acquired AMR determinants and 481 resistance phenotypes. We would note, however, that, as part of our sample consisted of isolates 482 that were resistant to one or more antibiotics, our choice of isolates might overestimate the 483 overall PPV, while underestimating the NPV. Incorporating mutational resistance also increased 484 PPV and decreased NPV for certain drugs, especially fluoroquinolones and macrolides, as 485 resistance to these drugs was predominantly mutational and not due to acquired AMR genes. The 486 E. coli sample was small (n = 47), and most E. coli isolates were susceptible to most antibiotics, 487 leading to very high consistency. In S. enterica, discrepancies in aminoglycoside resistance and 488 fluoroquinolone resistance typically arose from acquired resistance genes conferring 489 intermediate MICs or MICs at the high end of the susceptible range. As other studies in 490 foodborne pathogens have demonstrated (51, 54), clinical breakpoints, while obviously critical 491 for appropriate treatment, do not always correspond to the presence or absence of resistance 492
genes. 493
Beta-lactam resistance in S. enterica showed high correlation between resistance phenotypes 494 and genotypes overall. Elevated MICs and intermediate susceptibility amoxicillin-clavulanic 495 acid phenotypes in S. enterica were associated with the presence of beta-lactamases other than 496 blaCMY. NCBI's Pathogen Detection system (http://ncbi.nlm.nih.gov/pathogens), as part of a 497 collaboration with the FDA GenomeTrakr (58), CDC PulseNet (59), and USDA-FSIS, routinely 498 clusters genomes by sequence similarity, including the isolates described in this report, to 499 support outbreak and traceback investigations of clonal isolates. We determined that these 500 isolates belong to different SNP clusters, and so it does not appear that this pattern stems from 501 chance sampling of a single clone with an unknown resistance mechanism, though we cannot 502 rule out an unknown, common mechanism of decreased susceptibility. One possible explanation 503 why blaPSE family, blaHER, and blaTEM beta-lactamase carrying isolates would display this 504 phenotypic difference could be that these beta-lactamases are overproduced in the presence of 505 amoxicillin-clavulanic acid; overexpression of blaTEM-1 in E. coli confers amoxicillin-clavulanic 506 acid resistance(60). Alternatively, changes in permeability or efflux could lower the intracellular 507 concentration of either the drug or the inhibitor, conferring intermediate or decreased 508 susceptibility. 509
As found in previous studies, resistance to macrolides and quinolones in these C. coli and C. 510 jejuni (11) is largely due to point mutations. When we screened for point mutations in gyrA and 511 23S, we were able to predict phenotypes with extremely high accuracy. This highlights the 512 importance of point mutations in determining resistance phenotypes. Future editions of 513
AMRFinder will incorporate point mutation information for Campylobacter, E. coli, and S. 514
enterica. 515
Comparing AMRFinder to ResFinder revealed the importance of annotation and of a 516 comprehensive AMR reference gene database. Protein length variation, when working with 517 AMR proteins, can yield false conclusions. For any AMR gene detection system, incomplete or 518 incorrect databases can lead to AMR gene identification errors. 519
We also found that there were instances where the highest scoring ResFinder hit was either 520 incorrect due to absence of a sequence specific enough to make the correct call or to a reference 521 nucleotide sequence that was divergent from the correct sequence. One case was the aac(6') 522 family aminoglycoside modifying enzyme. Slight nucleotide changes that result in protein 523 differences can result in the gain or loss of fluoroquinolone and aminoglycoside resistance (61). 524
We also observed miscalls of QnrB alleles (quinolone resistance) and OXA-61 family beta-525 lactamases due to the closest nucleotide hit not corresponding to the correct protein hit. 526
AMRFinder, by having a nested hierarchical classification of AMR proteins into families, is able 527 to appropriately name novel AMR genes, which can avoid imputing incorrect function by 528 overspecifing the gene name. Without a clear interpretation of what similarity, but not complete 529 identity, to known AMR genes means, using a 'highest scoring hit' approach can lead to false 530 conclusions regarding AMR gene content. 531
Although allele miscalls might appear to be minor, and in many cases might not affect 532 susceptibility patterns, there are cases where these differences have profound effects on the 533 predicted resistance phenotype. As mentioned above, very minor differences in aminoglycoside 534 modifying enzymes can result in significant differences in susceptibility. Recent work with KPC 535 family beta-lactamases has revealed that a subset of alleles, including blaKPC-8, are not only 536 resistant to carbapenemases, but also ceftazidime-tazobactam (62). blaKPC-8 was first described in 537 2008 before ceftazidime-tazobactam existed as a treatment option. In some circumstances, 538 accurate identification down to the allele level is crucial to characterizing the relationship 539 between resistance genotype and phenotype. Comparisons in this study used older versions of 540 both the AMRFinder and Resfinder databases out of necessity, as both systems are continuously 541 improving their databases. Since we locked down the databases for both systems, as of Sept. 1, 542 2018, the Resfinder database has grown from 2,254 nucleotide sequences to 3,307 (a 35% 543 increase), and the AMRFinder database has increased by 17%, from 3,921 protein sequences to 544 4,579. These improvements should increase the accuracy of both systems. 545
Note that reliability of WGS-based methods is dependent on the accuracy of the underlying 546 WGS data. Low-level contamination or poor-quality sequence data can lead to inaccurate 547 assessments; this is a particular problem with 'greedy' assemblers that will assemble very low 548 coverage regions. Consensus assemblers run the risk that nearly identical orthologous genes or 549 low-level sequencing contamination might yield an incorrect sequence. Low-quality assemblies 550 can also result in partial genes, making assessment of resistance genes challenging. To increase 551 the accuracy and reliability of AMR gene identification, NCBI is developing an assembler that 552 emphasizes base accuracy, increasing the reliability of allele identification (63). 553
In analyzing these data, we also encountered several issues. There are two competing, 554 partially overlapping aminoglycoside modifying enzyme nomenclature systems. This makes 555 constructing reference gene databases, as well as validating them, extremely difficult. We also 556 discovered that, in developing the genotype-phenotype matrix, there are many alleles and genes 557 that either have not been characterized phenotypically at all, or only against a subset of 558 antibiotics. This was a particular problem with the beta-lactamases, where in some cases alleles 559 were characterized phenotypically before the advent of currently used drugs. In addition, some 560 genes are described very broadly. Terms such as 'cephalosporin-hydrolyzing' or 561 'aminoglycoside-modifying' do not aid accurate prediction. While these terms can be useful 562 when confronted with a novel allele or gene, in that they avoid making unwarranted statements 563 about phenotype, we would encourage more phenotypic assessment of novel and existing genes 564 using well-standardized methods and quality control, such as the CLSI or EUCAST standards, to 565 guide WGS-based methods and increase our basic understanding of AMR. It would also help to 566 have more phenotypic data publicly available and linked to existing genome sequences 567 (https://www.ncbi.nlm.nih.gov/biosample/docs/antibiogram/). 568
In AMRFinder, we have adopted a protein-focused approach, as opposed to a nucleotide-569 oriented approach, for several reasons. First, protein annotation and similarity comparisons 570 against both reference proteins and using HMMs with appropriate cutoffs can aid in determining 571 if the gene is functional, whereas a nucleotide approach can miss nonsense mutations. Second, 572 the protein sequence encodes the AMR function. Even single amino acid changes can 573 significantly alter resistance phenotypes, and this variation should be explicitly captured. Third, 574 there can be discordance between nucleotide and protein sequences, leading to the mis-575 assignment of alleles, and thus potentially to incorrect prediction of AMR phenotypes. Note, 576 however, that there can be upstream mutations that interfere with gene expression, and that these 577 types of mutations are not being reported by AMRFinder. For example, blaKPC alleles in the 578 context of different Tn4401 variants are expressed at different levels (64, 65) . Even when we 579 used both nucleotide and protein approaches, and removed isolates that had genotype-phenotype 580 discrepancies among three or more drug classes, we still observed that 17% of isolates had one 581 or more discrepancies between the resistance genotype and the observed antibiogram. Even with 582 high consistency for individual tests, isolates tested on multiple drugs will likely have one or 583 more discrepancies as a simple statistical property. For example, 21% of isolates tested against 584 twelve antibiotics with a consistency of 98% would have one or more errors (assuming an equal 585 consistency rate for each antibiotic). Further technical refinements will be needed to lower the 586 per-isolate discrepancy further, if clinical prediction is a primary goal. 587
The tool we have described, AMRFinder, uses a combined protein BLAST and HMM 588 approach. BLAST can identify complete or near matches to known genes. HMMs based on 589 curated data, on the other hand, can identify putative resistance genes that fall below arbitrary 590 BLAST thresholds, enabling the recognition of novel resistance genes. By integrating both of 591 these methods, we are able to assign the most specific functional name possible to the AMR 592 protein (66). 593
While AMRFinder is a powerful tool for identifying acquired resistance genes, our 594
Campylobacter results highlight the importance of assessing the role of point mutations. To 595 better understand the context in which AMR genes occur, NCBI is also developing a biocide and 596 metal resistance database to screen for genes linked to resistance to those compounds. The latest 597
AMRFinder software, source code, and databases are publicly available at 598 https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/. While this study 599 examined foodborne pathogens, NCBI's Pathogen Detection system, which facilitates the 600 analysis of food-borne and clinical isolates to aid outbreak and traceback investigations, uses 601 isolates observed with that MIC and genotypes. In the side legend, the number in parentheses is 841 the number of isolates with the corresponding genotype. "No genes" are those isolates lacking 842 any predicted fluoroquinolone resistance genes. oqxAB indicates the presence of these 843 fluorquinolone resistance genes in an isolate. "qnr" indicates the presence of one of the following 844 Qnr family genes: QnrB2, QnrB19, QnrB77, QnrS1, QnrS2, or an unassigned QnrB family 845 allele. "oqxAB, qnr" indicates an OqxAB, QnrB19 genotype. Point mutations are indicated by 846 the gene in which they occurred, followed by the site and changed residues. 847 Fig. 3 : Unexpected beta-lactamases confer decreased susceptibility to amoxicillin-clavulanic 848 acid in S. enterica. X-and y-axis as above. Allelic variants within a beta-lactamase family are 849 grouped together under the family name; an isolate can have multiple alleles belonging to the 850 same family. "blaPSE" family beta-lactamases are either CARB-2 or unassigned CARB alleles. 851 "blaCMY" family beta-lactamases were either novel blaCMY alleles or the CMY-2 allele. 852 "blaHER" indicates either the HER-3 allele or a novel HER-family allele. "blaTEM" indicates 853 either a novel TEM allele, or TEM-1 "No genes" indicates those isolates lacking beta-854 lactamases. 855 Fig. 4 a, b : Gentamicin and kanamycin resistance in S. enterica. Format as described for 856 Figure 2 except aminoglycoside modifying genes are grouped together by family. "No genes" 857 are those isolates lacking any predicted gentamicin and kanamycin resistance genes respectively. 858 The number of isolates with genotypes consistent with either phenotypic susceptibility or resistance to a given antibiotic is shown, with number of isolates with genotypes inconsistent with either susceptibility or resistance to a given antibiotic displayed in parentheses; values of zero in parentheses have been dropped for clarity. c "% consistent" describes the percentage of isolates with a phenotype consistent with genotype. d NC means the value cannot be calculated as there are no expected resistant isolates. e For ciprofloxacin, # resistant included isolates with intermediate and resistant MIC results. aOverall consistency was 96.7% with PPV = 0.904 and NPV = 0.982. b The number of isolates with genotypes consistent with either susceptibility or resistance to a given antibiotic is shown, with number of isolates with genotypes inconsistent with either susceptibility or resistance to a given antibiotic displayed in parentheses. Values of zero in parentheses have been dropped for clarity. c "% consistent" describes the percentage of isolates with a consistent phenotype. For macrolides and fluoroquinolones, consistency estimates include point mutation data. d NC means the value can not be calculated as there are no expected resistant isolates. aOverall consistency was 98.9% with PPV = 0.971 and NPV = 0.992. b The number of isolates with genotypes consistent with either susceptibility or resistance to a given antibiotic is shown, with number of isolates with genotypes inconsistent with either susceptibility or resistance to a given antibiotic displayed in parentheses. Values of zero in parentheses have been dropped for clarity. a In ten cases, ResFinder was unable to detect these as the nucleotide sequence was too divergent from any sequence found in the database. In 101 instances, there was no gene in the ResFinder database with >90% DNA sequence similarity to the predicted genes.
b Frameshifts led to early stop codons, resulting in stop codon positions that differed by more than 40bp between the two methods. Fig. 1 : Data processing and analysis flow. Processing steps and isolate inclusion and exclusion criteria are indicated by arrows, with the number of isolates retained in each phase indicated in the colored boxes. Thirty-eight isolates were excluded if their AST phenotypes in three or more drug classes differed from predictions based on acquired AMR genes.
